Diligence memo · auto-generated · as of July 2, 2026
Cleave Biosciences, Inc.
Cleave Biosciences, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Cleave Biosciences, Inc. operates in Biotechnology, based in BURLINGAME.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cleave Biosciences, Inc. has raised $38M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $26M on 2016-06-16.
Most recent recorded round closed around 2019-06-04.
Valuation (modeled)modeled
Provath models Cleave Biosciences, Inc. at approximately $475M (range $24M–$1.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.77× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era. Within the normal band (77% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 36 months.
Last raise 7.1 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 78% of Biotechnology peers (4293 compared).
Modeled value ranks above 82% of those peers.
Closest niche peers: Pandion Therapeutics Holdco LLC, Ocular Therapeutix, Inc, Insilico Medicine Cayman TopCo, Purigen Biosystems, Inc., Lucira Health, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.